Across TCGA pan-cancer cohorts, SNORD115-18 Mutation is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated SNORD115-18 data layer compared with 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SNORD115-18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNORD115-18 expression acts as an unfavorable survival marker.

BLCA, UCEC, and LUSC are the cancer types where SNORD115-18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.139	0.572	.026	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.445	0.746	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SNORD115-18 tumor-vs-normal RNA expression · all SNORD115-18 data types